A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure

Helicobacter

Volumn 17, Issue 4, 2012, Pages 264-268

  Fakheri, Hafez ^a   Bari, Zohreh ^b   Sardarian, Hossein ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Furazolidone; Helicobacter pylori; Second line therapy; Sequential

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; FURAZOLIDONE; PANTOPRAZOLE; TINIDAZOLE;

ADULT; AGED; AMNESIA; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DISEASE CONTROL; DIZZINESS; DRUG COST; FEMALE; FLUSHING; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; MALAISE; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 84863588504     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00946.x     Document Type: Article

References (37)

1. Egan BJ, Marzio L, O'Connor H, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2008;13(Suppl 1):35-40.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007;56:772-81.
3. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
4. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007;12(Suppl 2):50-8.
5. Nam TM, Lee DH, Kang KP, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Kor J Gastrointest Endosc 2008;36:200-5.
6. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
7. Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006;12:2313-9.
8. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
9. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
10. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79; quiz 1080.
11. Hsu PI, Wu DC, Wu JY, DY G. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14days? Helicobacter 2011;16:146-52.
12. Zullo A, Hassan C, Cristofari F, Iegri C, De Francesco V. How to manage Helicobacter pylori after sequential therapy failure. J Clin Gastroenterol 2010;44:459-60.
13. Shehada S, Srugo I, Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter 2007;12:645-7.
14. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007;39:1001-5.
15. Zullo A, De Francesco V, Hassan C, Panella C, Morini S, Ierardi E. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy 2006;3:251-4.
16. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
17. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline - comparison of three 3-year studies. Arch Iran Med 2010;13:177-87.
18. Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol 2009;25:549-56.
19. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17:3971-5.
20. Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential therapy for Helicobacter pylori eradication: The Time is Now! Therap Adv Gastroenterol 2009;2:317-22.
21. Gisbert JP, Pajares JM. Helicobacter pylori"rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72.
22. de Boer WA, Kuipers EJ, Kusters JG. Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use? Dig Liver Dis 2004;36:311-4.
23. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007;370:1010-2.
24. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two-second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24.
25. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
26. Kwon DH, Lee M, Kim JJ, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001;45:306-8.
27. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000;14:211-5.
28. Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-6.
29. Daghaghzadeh H, Emami MH, Karimi S, Raeisi M. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran. J Gastroenterol Hepatol 2007;22:1399-403.
30. Buzas GM, Jozan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2007;22:1571-81.
31. Sanches B, Coelho L, Moretzsohn L, Vieira G Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter 2008;13:572-6.
32. Felga GE, Silva FM, Barbuti RC, Navarro-Rodriguez T, Zaterka S, Eisig JN. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J Gastroenterol 2008;14:6224-7.
33. Gu LY, Lin WW, Lu H, Chen XY, Ge ZZ, Li XB. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study. Helicobacter 2011;16:284-8.
34. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009;15:860-4.
35. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004;19:89-93.
36. Fakheri H, Fakheri M, Shahmohammadi S. Efficacy of short-duration Furazolidone in two different quadruple regimens for H. pylori eradication. Pak J Med Sci 2011;27:887-91.
37. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012;17:43-8.